The Association Between Myasthenia Gravis and Higher Extrathymic Cancer Risk
Brain and Behavior · 2025-01 · 15 (1)
DOI: 10.1002/brb3.70143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, online erschienen am 19.01.2025. Verfasst von Mohamed Khateb und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Rambam Medical Center, Haifa, Israel. Hauptthemen laut MEDLINE: Myasthenia Gravis, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Myasthenia gravis (MG) is strongly associated with thymic tumors, but whether it is also associated with extrathymic cancers is debatable or whether MG can be considered a paraneoplastic disorder for extrathymic cancers.
Methods
This is a retrospective analysis of the MG cohort for 23 years' time (January 2000 to May 2023), extracting cancer rates with clinical, electrophysiological, and biochemical cancer associations and the effect of chronic medications.
Results
We identified 436 patients with MG and 3924 controls. The median age at symptom onset was 64 (5–93 years) for males and 54 (1–87 years) for females. MG symptoms at onset were recorded as ocular (60%), strictly bulbar (10%), or generalized (23%). Extrathymic cancer was found in 32% of MG patients. In 3%, thymic and extrathymic cancers co‐occurred. Compared to controls, neurology (12.2%, 159/1308), internal medicine (24.4%, 319/1308), or rheumatology (12%, 157/1308), MG patients had significantly higher rates of extrathymic cancers ( p < 0.001). Compared to the rheumatology group, the cancer relative risk of 2.97, CI = 2.5–3.4. Furthermore, the prevalence of extrathymic cancers was significantly increased within the paraneoplastic time window, defined as ±5 years from cancer diagnosis to myasthenia onset ( p < 0.01).
Conclusion
MG was significantly associated with an increased risk of extrathymic cancers, particularly within the paraneoplastic time window. These findings suggest that MG might potentially behave as a paraneoplastic disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Rambam Medical Center, Haifa, Israel.
- Department of Data Analysis and Information Systems, Rambam Medical Center, Haifa, Israel.
- Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Mohamed Khateb
Zitieren
APA
Khateb, M., Zant, M. A., Bsoul, A., Karny, T., Yarnitsky, D., & Shelly, S. (2025). The Association Between Myasthenia Gravis and Higher Extrathymic Cancer Risk. Brain and Behavior, 15(1). https://doi.org/10.1002/brb3.70143
Vancouver
Khateb M, Zant MA, Bsoul A, Karny T, Yarnitsky D, Shelly S. The Association Between Myasthenia Gravis and Higher Extrathymic Cancer Risk. Brain and Behavior. 2025;15(1). doi:10.1002/brb3.70143
BibTeX
@article{Khateb2025,
author = {Khateb, Mohamed and Zant, Mai Abu and Bsoul, Alaa and Karny, Tomer and Yarnitsky, David and Shelly, Shahar},
title = {The Association Between Myasthenia Gravis and Higher Extrathymic Cancer Risk},
journal = {Brain and Behavior},
year = {2025},
volume = {15},
number = {1},
doi = {10.1002/brb3.70143}
}
EUVIMED